Abstract Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents. Immunomodulatory drugs are used frequently in its treatment. Using the nominal group technique (NGT) and Delphi method, we created a multidisciplinary, evidence-and consensus-based treatment guideline for JIA based on a systematic literature analysis and three consensus conferences. Conferences were headed by a professional moderator and were attended by representatives who had been nominated by their scientific societies or organizations. 15 statements regarding drug therapy, symptomatic and surgical management were generated. It is recommended that initially JIA is treated with NSAID followed by local glucocorticoids and/or methotrexate if unresponsive. Complementing literature evidence with long-standing experience of caregivers allows creating guidelines that may potentially improve the quality of care for children and adolescents with JIA.
1. Introduction
Background, aims and addressees
Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for Rheumatology (ILAR) [1] . JIA is a highly heterogeneous disorder. Some of the subtypes of JIA are clearly distinct from others, also in regard of immunopathophysiology, e.g. systemic onset of JIA is now thought to be an autoinflammatory disease. Treatment of JIA subtypes may thus vary significantly [2] . JIA shows substantial impact on patients' physical abilities, psychological function and quality of life [3, 4] . Therefore, treatment goals are pain relief, the elimination of active disease, the normalization of physical function, the achievement of normal growth and development and improvement of quality of life. Appropriate initial management, continuous, comprehensive and consistent care offer the chance of the prevention of long term sequels [5, 6] . The German consensus group for treatment of JIA systematically developed guidelines for treatment of JIA in 1999, 2005 and 2008 [7, 8] . Our guideline is addressed to physicians in medical practices and hospitals, allied health professionals, physiotherapists, occupational therapists and all people who are involved in the treatment, care and follow-up of children or adolescents with JIA. Our aim is to provide clear, evidence-and consensus based recommendations for the treatment of children and adolescents with JIA within a multidisciplinary setting. The guideline focuses on JIA and does not cover the issue of treatment resistant cases, complex or unusual forms of arthritis and does not consider all ILAR subtypes of JIA individually. Subtype specific recommendations are highlighted separately, e.g. treatment schemes for oligo-, polyarticular or systemic onset JIA.
Methodology

Members of the consensus group and consensus conferences
Scientific societies and organizations (Table 1) , representing pediatricians in medical practices and hospitals, adult and pediatric rheumatologists, orthopedic surgeons, ophthalmologists, surgeons, physiotherapists, psychologists, national and local support-groups for parents and children, nominated representatives for the participation in consensus conferences. The scope of the conferences was the implementation of evidence and consensus based guideline for the treatment of JIA in children and adolescents. Consensus conferences were held at Duesseldorf respectively Krefeld (Germany) on the 9th of May 2007, 1st of August 2007 and 15th of January 2010 and were all attended by N 95% of the representatives.
Literature search and literature review
Based on existing guidelines [7, 8] we conducted a systematic literature search in Medline (http://www.ncbi.nlm.nih.gov/ pubmed/) (deadline of search: 15th January 2010; terms: "juvenile idiopathic (rheumatoid) arthritis" and "therapy"; limits: "humans", "published in the last 3 years", "all child: 0-18 years", "clinical trial"). Studies relating to diagnosis of JIA, uveitis, vaccination, transition, rofecoxibe, Casupplementation and costs were excluded manually. The exclusion was necessary due to varying target groups and loss of market approval by European Medical agency (EMA) respectively [9] . Final results of the literature review are as shown in Fig. 1 . These studies were evaluated for quality of methodology, following the definitions of evidence level and recommendation grade as published by Feldmann et al. [10] (Table 2 and  Table 3 ). Thirteen studies were judged as relevant for the 2010 update of treatment guidelines for JIA (Table 4) . To draft guideline statements, the core conclusions of studies were discussed and formal consensus building followed the nominal group technique (NGT) [11] and Delphi method [12] .
Consensus process
The consensus process was externally and independently supervised by the Association of the Scientific Medical Associations (AWMF), who has membership of Council for International Organizations of Medical Sciences (CIOMS). The AWMF coordinates the systematic development of diagnostic and treatment guidelines for medical, scientific societies and organizations in Germany.
Consensus building: nominal group technique (NGT)
Consensus building was headed by a professional moderators (H.S., I.K.). The moderator of the consensus conferences explained the purpose, method and procedure of consensus finding. Representatives gave brief presentations of literature and core conclusions for the guideline draft. A formal consensus process led to adoption of guidelines for treatment of JIA. As formal consensus procedure we used NGT, involving six stages:
1. Silent review of the guideline draft and noting of comments and ideas by the participants. During this period, participants did not consult or discuss with others. 
2010)
2. Collocation of comments and ideas by the moderator, using the words of the participants. 3. Clarification and substantiation of comments and ideas on alternative guideline statements, by the participants. 4. Reconcilement of the manuscript and all alternative guideline statements.
5. Discussion of statements and further explanation of any of the comments that were not clear to all participants. Each member of the consensus group contributed to the discussion. The moderator kept the process as neutral as possible, avoiding judgment and criticism. 6. Final reconcilement for statements for guideline. Table 3 Recommendation grade [10] .
Recommendation grade Definition
A
There is good evidence to support the recommendation that the intervention be performed. B
There is fair evidence to support the recommendation that the intervention be performed. C There is poor evidence regarding the value or harm of the intervention; recommendations may be made on other grounds. D
There is fair evidence to support the recommendation that the intervention not be performed. E There is good evidence to support the recommendation that the intervention not be performed. The conference guideline topics were reviewed and edited by working groups. After the first consensus conference, statements were adopted by NGT and additional proposals for schemes of treatment strategies of JIA were collated.
Consensus finding: method of Delphi
Three out of 15 statements remained without consensus after NGT. These statements comprise the utility of etanercept (treatment resistant polyarticular JIA), sulfasalazine (treatment resistant JIA) and anakinra (treatment for refractory SoJIA). Therefore, they were sent to all participants of consensus conferences via email. To each of them participants should state one of three votes ("agree", "do not agree" or "alternative proposal") (1st round of Delphi). The results were summarized and the statements, which remained with no consensus after 1st round of Delphi, were sent to participants again (2nd round of Delphi). After 2nd round of Delphi results were sent to external review.
External review and adoption
The guideline manuscript has been reviewed in 2007 by national experts in German Rheumatology: Huppertz (Bremen, Germany), Michels (Garmisch Partenkirchen, Germany) and Specker (Essen, Germany). The comments of external reviewers (H.I. Huppertz) to the 2011 manuscript were involved within the 3rd round of Delphi. External review enabled adoption of the guidelines' core conclusions and statements with strong consensus, i.e. 95% agreement by representatives of participating scientific societies and organizations.
Results: treatment guidelines
Drug-based therapy
Drugs used in treatment of JIA are summarized in Table 5 . Proposed schemes of treatment of JIA are shown in Fig. 2 . The following paragraphs will highlight specific adverse reactions and introduce the 13 studies relevant for the 2010 update of treatment guideline for JIA briefly. For detailed information about prescribing information including: indication, contraindication, drug dosage, route of administration, monitoring and product characteristics, the consensus group recommends consulting national drug data bases, e. g. www.roteliste.de (German database of drugs with national market approval) or www.fda.org or www.ema.europa.eu.
Non-steroidal anti-inflammatory drugs (NSAIDs)
Commonly, NSAIDs are well tolerated. Main side effects of NSAIDs are stomach irritation, dyspepsia and-in rare cases-nephritis. Cephalgia and behavioral changes can be associated with the administration of ibuprofen. Pseudoporphyria is not uncommon in patients treated with naproxen. Pain relief has been demonstrated for Naproxen [13] [14] [15] , Diclofenac [15, 16] and Ibuprofen [17] (evidence level I) and for Indometacin [18] and Meloxicam [19] (evidence level II). Efficacy of Celecoxibe has been demonstrated in a randomized, double blind multicenter study [20] . 95% of 212 patients entered the 12 week open label phase, after a 12 week double blind phase in three treatment groups (Celecoxibe 6 mg/kg/d versus Celecoxibe 12 mg/kg/d versus Naproxen 15 mg/kg/d). Both dosages of Celecoxibe showed comparable efficacy compared to Naproxen. Safety, i.e. number of adverse events (AE) did not differ significantly between Celecoxibe versus Naproxen.
Glucocorticoids
Glucocorticoids (GC)-local administration.
The use of intra-articular crystalline corticoids is highly potent and has a rather low rate of complications (evidence level II) [21, 22] . They might be administered as first line therapy. Response rate was significantly higher with triamcinolone hexacetonide than with triamcinolone acetonide at 6 months and this difference was sustained to 24 months [21, 22] . These findings were independent of duration and extent of disease [21, 22] . Simultaneous intra-articular steroid injections are preferable to consecutive injections at different time points (limited suppression of hypothalamicpituitary-adrenal axis) [23] . Side effects, e.g. local necrosis of fat tissue, are seen in approximately 2% of injections [22] . Working under sterile conditions, the risk of infection is low. 
Consensus statement.
Intra-articular injections of crystalloid corticosteroids (triamcinolone hexacetonide) are recommended and can be part of the first line treatment. Improvement of local inflammation, pain, swelling and range of joint movement has been demonstrated (evidence level II, recommendation grade A). Triamcinolone hexacetonide is more efficient than triamcinolone acetonide inducing local remission (evidence level I, recommendation grade B). GC in JIA published, thus leading to "just" evidence level III. Different recommendations of dosage and therapy regimes are listed in Table 5 (evidence level III for all recommendations) [18, [24] [25] [26] [27] [28] . Frequency and seriousness of deleterious effects correlate mainly to duration of therapy and dosage of GC administered. Main side effects are: iatrogenic Cushing's syndrome, growth disturbance, weight gain, mood changes. Higher dosage carry the risk of increased vulnerability to infection, hypertension, osteoporosis, thrombosis, diabetes, gastro-intestinal ulceration, cataract, glaucoma, atrophy of subcutaneous fatty tissue, steroid induced acne. To inform colleagues about GC treatment in a case of emergency and to reduce severe complications in long term treated patients, i.e. GC administration N 4 weeks, the supply of "Glucocorticoid ID cards" for patients might be useful. Consensus statement.
The systemic use of GC is recommended as fast acting drugs in highly active JIA. GC are used for the treatment of children and adolescents with SoJIA, organ manifestations of JIA (e.g. uveitis, pericardial effusion), sero-positive polyarticular JIA and for bridging time until the complete therapeutic effect of DMARDs (evidence level III, recommendation grade A).
MTX, biologic agents and immunosuppressive agents are used for the treatment of children and adolescents with polyarticular JIA, if NSAIDs or local GC treatment do not succeed. The combination of those drugs with NSAIDs and GC is feasible. A common characteristic of MTX, biologic agents and immunosuppressive agents is the delayed onset of therapeutic effect, i.e. up to 3 months or even longer after commencing treatment.
Long-term use of systemic GC is not recommended. Continuous administration of ≥0.2 mg Prednisolone equivalent per kg bodyweight (Bw) carries a high risk of adverse events and therefore is not recommended (evidence level III, recommendation grade A).
Consensus statement (continued)
Safe contraception is indicated during therapy with MTX, Azathioprine or Leflunomide and in the following 3 to 6 months after its discontinuation.
3.1.3.1. Methotrexate. Among DMARDs, MTX provides the mainstay of long-term therapy in JIA [29] [30] [31] [32] . In case of side effects, e.g. dyspepsia or nausea, prophylaxis with folic acid can be recommended (1 × 1 mg per day or 5 mg once a week, 24-48 h after application of MTX). Safe contraception is mandatory while receiving MTX. Safety and efficacy of MTX and its impact on quality of life of children with JIA have been investigated. Significant positive impact of MTX on all health-related quality of life health concepts has been shown; although the study has its limit due to different MTX dosages used within participating JIA patients [33] .
3.1.3.2. Purine analogs 3.1.3.2.1. Azathioprine. Efficacy has been investigated in a double blind placebo controlled study (32 patients). After 8 weeks of therapy the changes in disease activity measurement indicated a minor improvement in the Azathioprine group compared to the placebo group. At the end of the study, statistically significant differences between the groups were found for only 2 disease activity measurements [34] . Two patients were taken out of study, due to severe adverse events, e.g. leucopenia. Measurement of activity of Thiopurinmethyltransferase (TPMT) can be beneficial for avoidance of severe adverse events. [35] . Contraindications for Leflunomide are: renal insufficiency, severe immunodeficiency, depressed myelopoesis, and pancytopenia. An extensive half-life period (approximately 14 days) has to be taken in account, when administering Leflunomide. In combination with hepatotoxic DMARDs the risk of severe adverse events might increase, e.g. increased blood pressure is seen frequently. Safe contraception is mandatory. [36, 37] . One third of patients enrolled in the study discontinued treatment with Sulfasalazine, due to side effects, e.g. gastrointestinal symptoms, leucopenia [36] . Some experts use sulfasalazine in HLA-B27 positive JIA. Contraindications are Glucose-6-phosphatase deficiency and hypersensitivity against sulfonamides.
Hydroxychloroquine and chloroquine.
Hydroxychloroquine and Chloroquine have been subject to clinical trials for the treatment of JIA, even though efficacy was limited. Within three consensus conferences held in 2007 and 2010 the consensus group decided not to give a consensus statement on the use of chloroquine or hydroxychloroquine treatment, despite the fact that those drugs still might be used by some caregivers.
3.1.3.5. Biologic agents. Biologic agents are drugs, which selectively inhibit cytokines, cytokine receptors or directly bind to receptors of lymphocytes, e.g. CTLA-4, CD20. They include antibodies and fusion proteins. So far, all biological therapies are administered subcutaneously or intravenously.
3.1.3.5.1. TNFα-inhibitors. TNFα-inhibition with Adalimumab and Etanercept is efficient and safe (evidence level I) [38] [39] [40] [41] . Both drugs have been approved for JIA with polyarticular course. TNFα-inhibitors have become an integral part of the treatment of JIA. Potential risks of therapy are vulnerability for infection and-in a rare occasion-the induction of autoimmune disease. Prior to the start of treatment with TNFα-inhibitors chronic infections needs to be excluded or treated sufficiently, e.g. tuberculosis, hepatitis B or C.
In children with JIA treated with TNFα-inhibitors, malignancies, e.g. Lymphoma, have been reported. It remains unclear, if the rate of malignancies is increased in patients compared to the risk by having JIA itself. In response to a previous letter of the FDA (as reviewed in [42] ), the German Society for Pediatric Rheumatology (GKJR) has published official statements [43, 44] . The GKJR states, that treatment with TNFα-inhibition should be used very carefully; physicians need to be aware of co-medication, e. g. immunosuppressive drugs, and should monitor those patients closely [43] . There is insufficient data on all biologic agents-including TNFα-inhibition-to judge about the longterm risk for children and adolescents. MTX administration can be recommended, due to its proven safety and efficacy to reduce disease activity. MTX is used in case of insufficient therapeutic effect of NSAIDs and/or local GC administration, continuous need for systemic GC and/or highly active disease. Efficacy of MTX (orally or subcutaneously administered) is frequently achievable with a dosage of 10-15 mg/m² body surface (evidence level I, recommendation grade A).
Consensus statement.
Administration of Sulfasalazine or Leflunomide is recommended, if MTX or Etanercept do not show sufficient efficacy or cannot be used for other reasons (evidence level II, recommendation grade B).
been demonstrated in a randomized controlled withdrawal design trial for patients with polyarticular JIA [38] . Within an open extension study long term efficacy and safety have been documented over 8 years in 16/69 patients [39, 45] . There is data on more than 2000 patients, registered in European registries [46] [47] [48] . Currently, retrospective data shows a somewhat better efficacy of combining MTX or other DMARDs with TNFα-inhibition versus anti-TNFα therapy as single therapy [49] [54] demonstrated efficacy of Abatacept in patients with polyarticular JIA. 123 of 170 participants of study were enrolled in the 6 month double blind phase. Flares occurred in 33 of 62 (53%) patients who were given placebo versus 12 of 60 (20%) Abatacept patients during double blind phase. Adverse events (AE) did not differ in both groups, i.e. 37 AE in Abatacept versus 34 AE in placebo recipients. Some children may take 3 to 6 months or longer before their maximal response is achieved. 3% of patients developed reaction to the infusion [55] . Abatacept is approved by FDA and EMA for patients, who did not respond to prior MTX treatment. No data of long term effects of the use of Abatacept in JIA are available, due to the low numbers of patients treated so far.
Autologous stem cell transplantation (SCT)
There are studies on autologous SCT for treatment of refractory and severe forms of JIA (evidence level III) [56] . 22 Consensus statement.
The use of Anakinra or Tozilizumab can be recommended for treatment of children and adolescents with refractory SoJIA (evidence level II, recommendation grade A).
Consensus statement.
Efficacy of Etanercept and Adalimumab for the treatment of polyarticular JIA has been demonstrated. Therapy with TNFa-inhibition is indicated in case of insufficient therapeutic effect of NSAIDs and local GC administration and lack of response to MTX (evidence level I, recommendation grade A).
Consensus statement:
Patients with polyarticular JIA without systemic manifestation, refractory to treatment with MTX and TNF inhibition, might benefit from the use of Abatacept (evidence level III, recommendation grade C).
patients were enrolled in one study: 8 reached clinical remission, 7 were assessed as partial responders, 3 experienced relapse of the disease and 4 (18%) died as a consequence of MAS or immunosuppressive treatment [56] . Due to serious adverse events, including death, this therapeutic option is seen as the last treatment option.
3.2. Non-drug based therapy 3.2.1. Physiotherapy, occupational therapy and therapeutic appliances Physio-and occupational therapy are integral parts of the therapeutic concept in children and adolescents with JIA [57, 58] . Therapeutic goals of physiotherapy are: relaxation and pain relief, preservation or rehabilitation of physiological range of joint movement, prevention of contractures, stretching and activation of muscles, build-up of muscle force, and training of physiological movements.
Other forms of non-drug based therapeutic approaches rely on experts' opinion and are solely based on individual clinical experience. No controlled studies are available.
Sportive activity and exercise training
Positive impact of sportive activity on the general physical condition and on oxygen consumption has been demonstrated (evidence level II) [57] [58] [59] [60] . Adequate exercise training supports the physiological development and helps coping with JIA [58] . Prospective controlled long term studies are currently not available.
Surgical treatment
Toledo et al. investigated the role of arthroscopic synovectomy in JIA. They concluded that arthroscopy is a safe but only partially effective procedure in patients with oligoarticular JIA (evidence level/recommendation grade III/B) [61] .
Psychological, social intervention or socio-pedagogical care
There are no controlled or open studies focusing on psychological, social and/or socio-pedagogical intervention in children or adolescents with JIA. Recommendations are based on expert's opinion and personal experience solely.
Consensus statement.
Structured treatment by a properly trained physiotherapist/occupational therapist in combination with drug based therapy and instructions for disease adopted, self-sufficient daily exercise sessions are recommended to keep and to improve joint mobility (evidence level II, recommendation grade A). Custom-made therapeutic appliances for correction of axial misalignment, prevention of false weight bearing, stabilization of joints (e.g. hand-, finger-, and foot-ortheses) are recommended individually. The use of therapeutic appliances follows individual physician-directed advice. Efficacy has been demonstrated (evidence level I, recommendation grade B).
The implementation of thermotherapy, electroor ultrasound therapy, massage and lymph drainage is recommended. Application of cold appliances for acute joint inflammation is indicated (evidence level II, recommendation grade A). Electro-and ultrasound therapy are recommended for patients with tendosynovitis (evidence level III, recommendation grade B).
Exercise training is recommended depending on the extent of inflammation, number of affected joints and global disease activity. Sports with minor stress on joints is favorable (evidence level I, recommendation grade A).
In individual cases the indication for open or arthroscopic synovectomy can be considered if conservative therapy does not succeed (evidence level III, recommendation grade B).
An early psychological support within standard pediatric rheumatological care should be implemented, to apprehend and treat mental issues and behavioral syndromes associated with physiological disturbances and physical factors (evidence level III, recommendation grade A).
A socio-pedagogical care with regard to integration at school, professional and everyday life and formal education of parents and patients is recommended (evidence level III, recommendation grade A).
Addendum
Since the deadline January 15th, 2010 new papers have appeared that are of interest in the context of our guideline [55, [62] [63] [64] , in particular we refer to the ACR recommendations [65] and the most recent literature on the risk of malignancies in JIA in context with TNF blocking agent and independent of medication [42] , [66] . Moreover, there is a recent study on the use of Tocilizumab in polyarticular patients [67] . These papers will be discussed within the next consensus conference by NGT and considered for inclusion into the next edition of this guideline. On 6th of September 2011, our advanced search on www.clinicaltrial.gov (search terms: juvenile idiopathic arthritis; recruitment: open studies; study type: interventional study; age group: child (birth-17); intervention: drugs) led to 16 trials which are currently recruiting or will soon start recruiting.
Discussion
To develop clinical practice guidelines of high quality and validity, a formal consensus process and explicit methodological criteria for the production of guidelines are recommended [68] [69] [70] . Our guideline for the treatment of JIA in children and adolescents implements all these issues. The systematic literature search was terminated on 15th January 2010, leading to the most up to date guideline for JIA which is currently available. The deadline of the ACR recommendations as published recently by Beukelmann et al. was 5th of October 2009 [65] . By exclusion of case reports, trials without control groups, preliminary results published as abstracts on conferences and the strict graduation of the literature by the criteria of evidence based medicine, we aimed to give our guideline statements additional strength and a maximal validity. Newer original studies providing additional evidence for the treatment of JIA became available after our consensus process was finished, see Addendum. The results of these trials have to await the next NGT before inclusion into our recommendations.
Our updated systematic literature search in 2010 led to 13 relevant studies published after 30th June, 2007 (Fig. 1 , Table 4 ). Their results have to be interpreted with caution. First, trials in JIA are mainly based on limited numbers of pediatric patients, as the recruitment of a sufficient number of pediatric patients remains challenging. Second, trials are mainly designed for patients with polyarticular JIA or with oligoarticular onset and a polyarticular course (Table 4) . Most children with JIA do not have a polyarticular subtype of JIA, but an oligoarticular onset and course [71] . Thus, patients with oligoarticular JIA are heavily underrepresented in most of the current trials. Third, in 5 of the 13 studies the withdrawal study design has been used [40, 45, 50, 53, 54] . Lehmann reviewed the bias of withdrawal design trials in 2008 [72] . After a wash-in phase only responders to treatment are eligible for randomization. Thus the design preselects responders to the placebo effect who might retain their response throughout the entire study period. Further, there is a carryover effect of AE into the placebo group, so that significant differences in AE between groups may not become apparent. In the one placebo controlled trial without withdrawal design on TNFα-inhibition (Infliximab) no significant efficacy could be demonstrated between verum and placebo [31] .
To our knowledge there are two other guidelines that deal with the management of JIA as a whole (Table 6 ) [65] , [73] . Other guidelines are limited to the use of single drugs in JIA, e.g. biologic agents [74] , etanercept [75] . The Australian guideline (www.racgp.org.au/guideline/juvenileidiopathicarthritis) has not been published in a peer-reviewed journal. It is to provide recommendations for the early diagnosis and multidisciplinary management of JIA in the primary care setting for general practitioners (GPs) [73] . No recommendations are made regarding the use of GCs, DMARDs, immunosuppressive drugs or biologic agents [73] . The ACR recommendations uses the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument [65] , [76] which does not fulfill criteria of a proper consensus process and carries the risk, that experts vote for peer opinion, which might not reflect the true value. We used an advanced and linguistically validated version of the AGREE instrument: the "German Instrument for Methodological Guideline Appraisal (DELBI)", which has been developed in cooperation of the AWMF among others [77, 78] . We followed the highly structured Nominal Group Technique as described in Methodology. Our consensus group only considered formally board nominated representatives of multidisciplinary scientific societies and organizations (Table 1 ) and included patient's representatives, as this has been strongly recommended by the European League against Rheumatism (EULAR) recently [79] . The ACR mentions a parent representative within their task force panel, but leaves this representative anonymous. It remains unclear how ACR experts were selected and involved [65] . They defined treatment groups which have not been evaluated systematically so far. We used the ILAR classification system which has been repeatedly evaluated [80] [81] [82] .
By content there are major differences between the ACR recommendations and our guideline. a) Our guideline provides a detailed and systematic list of 20 drugs commonly used in the treatment of JIA (Table 5) , which has been an integrative part of our consensus conferences. The ACR recommendations do not provide information on approval status (Food and Drug Administration), indications for use and no specific differences on dosage regimes or frequency of daily application [65] , e.g. it refers to the 2008 ACR recommendations for the use of DMARDs in adult rheumatoid arthritis. b) The ACR recommendations provide a more early aggressive approach in the treatment of JIA. The ACR recommends MTX as first line treatment in patients (b 4 joints) with highly active disease [65] . To our knowledge there are only data to recommend MTX administration in cases of insufficient therapeutic effect of prior treatment with NSAID and/or GC [33] . c) The ACR recommends the use of TNFα inhibitors as escalation therapy for some patients with history of arthritis of 4 or fewer joints and refer to publications [38, 40] conducted in patients with polyarticular JIA or pauciarticular JIA with polyarticular course [65] . There is no evidence that TNF is safe and efficient in patients with oligoarticular JIA, a systematic, controlled clinical trial on this issue has not been done yet. d) We regard a brief trial of local or systemic administration of GC plus NSAID as a feasible first line treatment for patients with polyarticular JIA. The ACR recommends MTX without regard to disease activity at the initial stage [65] . We reached consensus to recommend the use of GC as bridging therapy until full onset of therapeutic effect of DMARDs. The ACR recommendations do not provide any recommendation for the use of systemic GC for patients with oligo-or polyarticular course of JIA except systemic onset of JIA. e) The ACR recommendations do not cover the topic of non-drug based therapy at all, although there is strong evidence that e.g. exercise training is a useful addition to drug treatment [57, 58, 60] .
Conclusion
In summary we present a treatment guideline for JIA on a consensus conference basis. We strongly advocate an interdisciplinary approach including surgery, physiotherapy, psychosocial intervention, physical therapy, medications, etc. and a strict formal consensus process in order to create statements that are most appropriate for the complex clinical situation of a child and family presenting with JIA and cover all aspects of JIA care. All German pediatric rheumatology sites are participating at the national pediatric rheumatologic database in the Deutsche Rheuma-Forschungszentrum at Berlin (DRFZ, www. drfz.de). It aims at quality assurance in Germany and monitors treatment behavior of pediatric rheumatologists by using internationally agreed criteria (e.g. joint count, global physician rating of disease activity, global parent rating of overall wellbeing, CHAQ, ESR, ACR-ped response or JADAS). The database will be used as a tool to monitor the application of our treatment guidelines. 
